About: Lorenza Rimassa

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Lorenza Rimassa Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher

Attributes	Values
rdf:type	Item
description	ikertzailea (eu) researcher (en) 연구원 (ko) গবেষক (bn) 研究者 (ja) chercheuse (fr) investigadora (es) ഗവേഷക (ml) araştırmacı (tr) дослідниця (uk) वैज्ञानिक (hi) изилдөөчү (ky) 研究者 (zh) հետազոտող (hy) onderzoeker (nl) researcher (en-ca) researcher (en-gb) researcher (en-us) hulumtuese (sq) investigadora (ca) investigadora (gl) investigadora (pt) investigadora (ast) ricercatrice italiana (it)
exact match	wds:Q38524354-AAD43C26-F4A7-419E-B4B2-829BB1D65838
exact match	https://scigraph.springernature.com/person.0733441746.71
rdfs:label	Lorenza Rimassa (en) Lorenza Rimassa (es) Lorenza Rimassa (it) Lorenza Rimassa (nl) Lorenza Rimassa (sl) Lorenza Rimassa (ast) ロレンツァ・リマッサ (ja)
skos:prefLabel	Lorenza Rimassa (en) Lorenza Rimassa (es) Lorenza Rimassa (it) Lorenza Rimassa (nl) Lorenza Rimassa (sl) Lorenza Rimassa (ast) ロレンツァ・リマッサ (ja)
name	Lorenza Rimassa (en) Lorenza Rimassa (es) Lorenza Rimassa (it) Lorenza Rimassa (nl) Lorenza Rimassa (sl) Lorenza Rimassa (ast) ロレンツァ・リマッサ (ja)
Scopus author ID	wds:Q38524354-084F67A7-A34A-4B86-A7AC-EEC2D6CE00A5
Scopus author ID	6602480388
given name	wds:Q38524354-DFAC0C46-CC4D-451B-A230-47B9C75AAB87
given name	Lorenza
instance of	wds:Q38524354-2AB340BB-B77E-4D36-855E-AD29C40762BA
instance of	Homo sapiens
occupation	wds:Q38524354-74F068E2-3137-4BEF-BEF8-DDEDE1D064B5
employer	wds:Q38524354-2EE72AC0-C5A5-4F4A-A158-F2B614F5595B wds:Q38524354-5684EB0B-2A61-42C0-BDD1-F05040EBE53B wds:Q38524354-5B377DDF-6612-45E0-BBE7-2311973007A6 wds:Q38524354-96F1E399-3AB3-4648-BA75-A6929BD0710E wds:Q38524354-D6A9319F-C273-45AC-992A-256689CADBD6 wds:Q38524354-E114C4E3-15F6-4349-AFB4-DB78AD92A9F6 wds:Q38524354-F2CBF915-4E4D-40B0-9815-65E821129897 wds:Q38524354-F877CB7B-FB31-4E64-A38A-AAA61E7CCA9B
sex or gender	wds:Q38524354-870AD096-CF2C-44C3-AF30-C3CB341329D7
SBN author ID	wds:Q38524354-16C21286-5C74-46FD-B717-BC6033A7F154
on focus list of Wikimedia project	wds:Q38524354-05252556-B9B1-4C0A-AEB8-C379D03843AF
family name	wds:Q38524354-b2aec2de-445b-7f32-9f2e-ca23058b5d53
occupation	researcher
employer	Humanitas University San Raffaele Hospital National Cancer Institute Humanitas Research Hospital
sex or gender	female organism
SBN author ID	MILV160008
on focus list of Wikimedia project	WikiProject COVID-19
family name	Rimassa
ORCID iD	wds:Q38524354-9EA4C5F0-FB6D-4F98-9902-263D17347B8D
Dimensions author ID	wds:Q38524354-BA9AF051-0512-4798-8A64-F7D933A2E9B5
ORCID iD	https://orcid.org/0000-0001-9957-3615
ORCID iD	0000-0001-9957-3615
Dimensions author ID	0733441746.71
ResearcherID	wds:Q38524354-CF6D22F2-D957-4B7C-85C1-FF3C19B2024A
Publons author ID	wds:Q38524354-8f63bc7d-5b08-49e7-93c0-4065430bc99b
ResearcherID	N-4884-2016
Publons author ID	1709212
IRIS HUNIMED author ID	wds:Q38524354-838CB8F8-3EBC-4D3C-A127-8C74E6480C13
IRIS HUNIMED author ID	01444
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q38524354
is author of	Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software